James L. Kepner

7.1k total citations · 1 hit paper
76 papers, 5.0k citations indexed

About

James L. Kepner is a scholar working on Statistics and Probability, Genetics and Neurology. According to data from OpenAlex, James L. Kepner has authored 76 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Statistics and Probability, 17 papers in Genetics and 16 papers in Neurology. Recurrent topics in James L. Kepner's work include Glioma Diagnosis and Treatment (17 papers), Statistical Methods in Clinical Trials (16 papers) and Optimal Experimental Design Methods (14 papers). James L. Kepner is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Statistical Methods in Clinical Trials (16 papers) and Optimal Experimental Design Methods (14 papers). James L. Kepner collaborates with scholars based in United States, Canada and Switzerland. James L. Kepner's co-authors include Henry S. Friedman, Larry E. Kun, Peter C. Burger, Kunle Odunsi, Brian N. Bundy, Christine B. Ambrosone, Achim A. Jungbluth, Haruo Ohtani, Hiroyoshi Nishikawa and Sara H. Olson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

James L. Kepner

73 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intraepithelial CD8⁺tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

2005 1.9k citations James L. Kepner et al. profile →

Peers

Countries citing papers authored by James L. Kepner

Since Specialization

Citations

This map shows the geographic impact of James L. Kepner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James L. Kepner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James L. Kepner more than expected).

Fields of papers citing papers by James L. Kepner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James L. Kepner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James L. Kepner. The network helps show where James L. Kepner may publish in the future.

Co-authorship network of co-authors of James L. Kepner

This figure shows the co-authorship network connecting the top 25 collaborators of James L. Kepner. A scholar is included among the top collaborators of James L. Kepner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James L. Kepner. James L. Kepner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Photopheresis in HIV-1 Infected Patients Utilizing Benzoporphyrin Derivative (BPD) Verteporfin and Light 2008 ·Current HIV Research ·Zale P. Bernstein, Thomas J. Dougherty, Sandra O. Gollnick, Stanley A. Schwartz, Supriya D. Mahajan, James L. Kepner, Adam B. Sumlin, Carleton C. Stewart, Paul K. Wallace, (unknown), (unknown), Bernard J. Poiesz	7
2	A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study 2007 ·Annals of Surgical Oncology ·Renuka Iyer, John F. Gibbs, Boris W. Kuvshinoff, Marwan Fakih, James L. Kepner, (unknown), David Lawrence, Milind Javle	56
3	Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP‐16: A Children's Oncology Group phase II study 2007 ·Pediatric Blood & Cancer ·David N. Korones, Paul G. Fisher, Cynthia S. Kretschmar, Tianni Zhou, Zhengjia Chen, James L. Kepner, Carolyn Freeman	83
4	A phase I and pharmacokinetic (PK) study of intravenous (IV) calcitriol and gefitinib assessing EGFR pharmacodynamic (PD) interactions through serial skin biopsies 2005 ·Cancer Research ·Marwan Fakih, Candace S. Johnson, Josephia R. Muindi, Jennifer D. Black, Patrick J. Creaven, Michael G. Brattain, James L. Kepner, (unknown), Donald L. Trump	1
5	A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children’s oncology group 2005 ·Journal of Neuro-Oncology ·Murali Chintagumpala, Henry S. Friedman, Clinton F. Stewart, James L. Kepner, Roger E. McLendon, Paul Modrich, Charles W. McCluggage, Peter C. Burger, Emi Holmes, Stephen J. Thompson, James T. Rutka, Jeff M. Michalski, Shiao Y. Woo, Susan M. Blaney, Larry E. Kun, (unknown), (unknown)	16
6	Postoperative Computed Tomography Scan Surveillance for Patients With Stage II and III Colorectal Cancer 2005 ·American Journal of Clinical Oncology ·Amir Mortazavi, Aasma Shaukat, (unknown), James L. Kepner, Marwan Fakih, Boris W. Kuvshinoff, Judy L. Smith, Milind Javle	10
7	Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? 2004 ·Diseases of the Esophagus ·Aasma Shaukat, Amir Mortazavi, Todd L. Demmy, (unknown), Neal Wilkinson, Gang Yang, James L. Kepner, M. M. Javle	11
8	Samples of exact k-stage group sequential designs for Phase II and Pilot studies 2004 ·Controlled Clinical Trials ·James L. Kepner, Myron Chang	13
9	The effectiveness of complete decongestive physiotherapy for the treatment of lymphedema following groin dissection for melanoma 2004 ·Journal of Surgical Oncology ·Christian S. Hinrichs, John F. Gibbs, Deborah Driscoll, James L. Kepner, Neal Wilkinson, Stephen B. Edge, (unknown), (unknown), William Kraybill	29
10	Phase 2 study of idarubicin in pediatric brain tumors: Pediatric OncologyGroup study POG 9237 2003 ·Neuro-Oncology ·ZoAnn E. Dreyer, Richard Kadota, Clinton F. Stewart, Henry S. Friedman, Donald H. Mahoney, Larry E. Kun, Charles W. McCluggage, Peter C. Burger, James L. Kepner, Richard L. Heideman	23
11	Paclitaxel for the Treatment of Progressive or Recurrent Childhood Brain Tumors: A Pediatric Oncology Phase II Study 2001 ·The American journal of pediatric hematology/oncology ·Craig A. Hurwitz, Lewis C. Strauss, James L. Kepner, Cynthia S. Kretschmar, Michael B. Harris, Henry S. Friedman, Larry Kun, Richard Kadota	45
12	Carboplatin is effective therapy for young children with progressiveoptic pathway tumors: A Pediatric Oncology Group phase II study 2000 ·Neuro-Oncology ·Donald H. Mahoney, Michael E. Cohen, Henry S. Friedman, James L. Kepner, (unknown), J. William Langston, Hector E. James, Patricia K. Duffner, Larry E. Kun	79
13	Burkitt lymphoma is immunophenotypically different from Burkitt-like lymphoma in young persons 2000 ·Annals of Oncology ·R. Hutchison, (unknown), James L. Kepner, Christine Fuller, Paul Bowman, Michael P. Link, Molly Schwenn, Joseph Laver, Sangeeta Desai, David A. Barrett, S B Murphy	19
14	Group Sequential Designs for Phase II Trials With Historical Controls 1999 ·Controlled Clinical Trials ·Myron Chang, Jonathan J. Shuster, James L. Kepner	11
15	Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma 1999 ·Genes Chromosomes and Cancer ·David A. Reardon, (unknown), Jack Sublett, Susan T. Ragsdale, Hao Li, James M. Boyett, James L. Kepner, A. Thomas Look	73
16	Pediatric Astrocytomas with Monomorphous Pilomyxoid Features and a Less Favorable Outcome 1999 ·Journal of Neuropathology & Experimental Neurology ·Tarık Tihan, Paul G. Fisher, James L. Kepner, Catherine Godfraind, Rodney D. McComb, Patricia T. Goldthwaite, Peter C. Burger	210
17	Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: A Highly Malignant Tumor of Infancy and Childhood Frequently Mistaken for Medulloblastoma 1998 ·The American Journal of Surgical Pathology ·Peter C. Burger, (unknown), Tarık Tihan, Henry S. Friedman, Douglas Strother, James L. Kepner, Patricia K. Duffner, Larry E. Kun, Elizabeth J. Perlman	315
18	On Rank Transformation Techniques for Balanced Incomplete Repeated-Measures Designs 1996 ·Journal of the American Statistical Association ·James L. Kepner, Dennis D. Wackerly	8
19	A monte carlo study of rank tests for repeated measures designs 1993 ·Communications in Statistics - Simulation and Computation ·Michael D. Ernst, James L. Kepner	5
20	Nonparametric Methods for Detecting Treatment Effects in Repeated-Measures Designs 1988 ·Journal of the American Statistical Association ·James L. Kepner, David Robinson	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact